- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04430192
Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy (LuTectomy)
August 17, 2023 updated by: Peter MacCallum Cancer Centre, Australia
Study of the Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Radionuclide Therapy Prior to Radical Prostatectomy in Men With High-risk Localised Prostate Cancer
This clinical trial will evaluate the dosimetry, efficacy and toxicity of Lu-PSMA in men with high PSMA-expressing high-risk localized or locoregional advanced prostate cancer (HRCaP) undergoing radical prostatectomy (RP) and pelvic lymph node dissection (PLND)
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
This open label, phase I/II non-randomised clinical trial will evaluate the dosimetry, efficacy and toxicity of Lu-PSMA in men with high PSMA-expressing high-risk localized or locoregional advanced prostate cancer (HRCaP) undergoing radical prostatectomy (RP) and pelvic lymph node dissection (PLND).
Patients will receive one or two cycles of 177Lu-PSMA followed by surgery.
The primary objective is to determine the radiation absorbed dose in the prostate and involved lymph nodes.
Secondary objectives include evaluating imaging response to therapy using PSMA-PET, biochemical response, pathological response, adverse effects of Lu-PSMA and surgical safety, and health-related Quality of Life (QoL).
Study Type
Interventional
Enrollment (Estimated)
20
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Victoria
-
Melbourne, Victoria, Australia, 3000
- Peter MacCallum Cancer Centre
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patient has provided written informed consent.
- Male patient aged 18 or over at the time of screening
- Histologically confirmed adenocarcinoma of the prostate, in a patient scheduled for RP and PLND with curative intent
High or high-intermediate risk localised or locoregional prostate cancer (HRCaP) by European Association of Urology (EAU) criteria, including any of the following:
- PSA > 20 ng/mL
- ISUP grade group 3-5
- Clinical T-stage by digital rectal examination (DRE) of T2c or higher
- N1 disease (involvement of lymph nodes at or below the bifurcation of the common iliac arteries)
- defined radiologically (CT/ MRI, or PSMA PET).
- High PSMA avidity on 68Ga-PSMA PET/CT, defined as an SUVmax of ≥ 20
- Normal baseline haematological function; haemoglobin 13.5-17.5g/dl), total white blood cell count (4-11 x 109/l), platelets (150-400 x 109/l), neutrophils (2-7.5 x 109/l) and lymphocytes (1-4 x 109/l)
- Normal baseline serum biochemistry; sodium 135-145 nmol/l, potassium 3.5-5 nmol/l, chloride 98-108 nmol/l, urea 3-9.2 nmol/l, creatinine 60-120μmol/l
- Willing and able to comply with all study requirements including all treatments and required assessments including follow up
Exclusion Criteria:
- Prostate cancer with significant neuroendocrine or other rare variant pathology
- Prior treatment for prostate cancer including radiotherapy and/or androgen deprivation therapy.
- Evidence of metastatic disease involving bone, viscera, or lymph nodes superior to the common iliac bifurcation based on CT, MRI, WBBS or PSMA PET/CT.
- Renal impairment [GFR < 60mL/min].
- Sjogren's syndrome.
- A history of or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 177Lu-PSMA-617 followed by prostatectomy
|
Patients 1-10 will be given 5GBq of 177Lu-PSMA.
Patients 11-20 will be given 2 cycles of 5GBq of 177Lu-PSMA, separated by 6 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine the radiation absorbed dose in the prostate and involved lymph nodes following one or two administrations of Lu-PSMA in men with HRCaP prior to radical prostatectomy
Time Frame: Determined using imaging at 4, 24 and 96 hrs after administration of Lu-PSMA
|
Establishing the absorbed radiation dose in the prostate and involved lymph nodes (Gy)
|
Determined using imaging at 4, 24 and 96 hrs after administration of Lu-PSMA
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the imaging response to therapy using PSMA-PET
Time Frame: 6 weeks following final administration of Lu-PSMA
|
PSMA PET response to therapy (complete metabolic response, partial metabolic response, stable metabolic disease, progressive metabolic disease)
|
6 weeks following final administration of Lu-PSMA
|
To evaluate the biochemical response to therapy
Time Frame: 6 weeks following final administration of Lu-PSMA
|
PSA response
|
6 weeks following final administration of Lu-PSMA
|
To evaluate pathologic response in the prostate following prostatectomy
Time Frame: After prostatectomy, approximately 6 weeks from final Lu-PSMA administration
|
Pathological response (complete response, minimal residual disease)
|
After prostatectomy, approximately 6 weeks from final Lu-PSMA administration
|
To evaluate toxicity of Lu-PSMA
Time Frame: Until 8 weeks after prostatectomy
|
Assessment of toxicity of Lu-PSMA using Common Terminology Criteria for Adverse Events (CTCAE) v5
|
Until 8 weeks after prostatectomy
|
To evaluate the surgical safety of prostatectomy following Lu-PSMA
Time Frame: Until 8 weeks after prostatectomy
|
Surgical safety will be assessed using using the Clavien-Dindo classification of surgical complications
|
Until 8 weeks after prostatectomy
|
To evaluate overall health-related Quality of Life (QoL)
Time Frame: baseline, immediately before 2nd cycle Lu-PSMA, immediately before surgery, 8 weeks post surgery, annually up to 3 years
|
QoL indices will be scored using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire
|
baseline, immediately before 2nd cycle Lu-PSMA, immediately before surgery, 8 weeks post surgery, annually up to 3 years
|
To evaluate prostate cancer health-related Quality of Life (QoL)
Time Frame: baseline, immediately before 2nd cycle Lu-PSMA, immediately before surgery, 8 weeks post surgery, annually up to 3 years
|
QoL indices will be scored using European Organisation for Research and Treatment of Cancer (EORTC) QLQ-PR25 questionnaire
|
baseline, immediately before 2nd cycle Lu-PSMA, immediately before surgery, 8 weeks post surgery, annually up to 3 years
|
To evaluate patient function and bother after prostatectomy
Time Frame: baseline, immediately before 2nd cycle Lu-PSMA, immediately before surgery, 8 weeks post surgery, annually up to 3 years
|
Indices will be scored using the Expanded Prostate Cancer Index Composite (EPIC)-26 questionnaire
|
baseline, immediately before 2nd cycle Lu-PSMA, immediately before surgery, 8 weeks post surgery, annually up to 3 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine the time to biochemical recurrence (BCR) [PSA>0.2 ng/mL post-RP]
Time Frame: To be determined as it is an exploratory endpoint up to 3 years
|
Biochemical recurrence (BCR) will be measured from the time of surgery to the first rise of the PSA to ≥0.2 ng/mL
|
To be determined as it is an exploratory endpoint up to 3 years
|
To determine the relationship between PSMA PET imaging parameters and absorbed dose
Time Frame: baseline PSMA PET within 45 days of Lu-PSMA administration
|
Determination of the relationship between screening PSMA PET imaging parameters including molecular tumour volume parameters and absorbed dose in the prostate and involved lymph nodes
|
baseline PSMA PET within 45 days of Lu-PSMA administration
|
To identify tissue and blood and serum biomarkers associated with clinical outcomes
Time Frame: To be determined as it is an exploratory endpoint up to 3 years
|
Determination of relevant predictive biomarkers associated with treatment outcomes and response
|
To be determined as it is an exploratory endpoint up to 3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Declan Murphy, Peter MacCallum Cancer Centre, Australia
- Principal Investigator: Michael S Hofman, Peter MacCallum Cancer Centre, Australia
- Principal Investigator: John Violet, Peter MacCallum Cancer Centre, Australia
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 6, 2020
Primary Completion (Actual)
December 22, 2022
Study Completion (Estimated)
December 30, 2023
Study Registration Dates
First Submitted
May 21, 2020
First Submitted That Met QC Criteria
June 10, 2020
First Posted (Actual)
June 12, 2020
Study Record Updates
Last Update Posted (Actual)
August 21, 2023
Last Update Submitted That Met QC Criteria
August 17, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19_245
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostatic Neoplasms
-
Technische Universität DresdenRecruitingOligometastatic Disease | Prostatic Cancer, Castration-ResistantGermany
-
Australian and New Zealand Urogenital and Prostate...Peter MacCallum Cancer Centre, AustraliaRecruitingCastration Resistant Prostatic CancerAustralia
-
British Columbia Cancer AgencySanofi; Ozmosis Research Inc.UnknownMetastatic Castration-Resistant Prostatic CancerCanada, Australia
-
Janssen Research & Development, LLCCompletedCastration-Resistant Prostatic NeoplasmsCanada, Belgium, United States, Spain, Netherlands, Italy, Russian Federation
-
Universität des SaarlandesRecruitingProstate Cancer Metastatic | Advanced Prostate Carcinoma | Castration Resistant Prostatic CancerGermany
-
Yinghao SunNot yet recruitingCastration-Resistant Prostatic Cancer
-
Institut Claudius RegaudWithdrawnProstatic Cancer, Castration-ResistantFrance
-
University Hospital, GrenobleTerminatedCastration-resistant Prostate CancerFrance
-
Michael Graham PhD, MDUniversity of Iowa; Holden Comprehensive Cancer CenterActive, not recruitingProstate Cancer | Prostatic Neoplasms, Castration-Resistant | Prostatic Neoplasm | Prostatic Cancer Recurrent | Prostatic Cancer MetastaticUnited States
-
Rio de Janeiro State UniversityCompletedProstatic Cancer | Prostatic NeoplasmBrazil
Clinical Trials on 177Lu-PSMA-617
-
Peking Union Medical College HospitalNational Institute for Biomedical Imaging and Bioengineering (NIBIB)RecruitingMetastatic Castration-resistant Prostate CancerChina
-
Centre Georges Francois LeclercNot yet recruitingPatients With Metastatic Castration-resistant Prostate Cancer
-
University of California, San FranciscoMerck Sharp & Dohme LLC; Prostate Cancer FoundationRecruitingProstate Cancer | Prostate Carcinoma | Metastatic Castration-resistant Prostate Cancer | Castrate Resistant Prostate CancerUnited States
-
Novartis PharmaceuticalsRecruitingProstate CancerUnited States
-
Vadim S KoshkinEli Lilly and Company; Prostate Cancer FoundationActive, not recruitingCastration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Castration-resistant Prostate Cancer | Metastatic Prostate Adenocarcinoma | Metastatic Castration-resistant Prostate CarcinomaUnited States
-
Peking Union Medical College HospitalRecruitingDiagnosis of Renal Cell Carcinoma on 68Ga-PSMA PET-CT and Radioligand Therapy With 177Lu-EB-PSMA-617Renal Cell CarcinomaChina
-
Peter MacCallum Cancer Centre, AustraliaUnited States Department of Defense; Advanced Accelerator Applications; Australian... and other collaboratorsActive, not recruitingMetastatic Hormone Naive Prostate CancerAustralia
-
Peking Union Medical College HospitalRecruitingAdenoid Cystic CarcinomaChina
-
Advanced Accelerator ApplicationsNo longer availableMetastatic Castration-resistant Prostate Cancer (mCRPC)
-
Australian and New Zealand Urogenital and Prostate...Astellas Pharma Inc; Endocyte; Prostate Cancer Research Alliance; National Health...Active, not recruitingMetastatic Castration-Resistant Prostate CancerAustralia